Innoviva, Inc. (NASDAQ:INVA) is one of the best affordable biotech stocks to invest in now. On August 11, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Innoviva, Inc. (NASDAQ:INVA) to $45 from$40 while keeping a Buy rating on the shares. Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling The same day, Oppenheimer initiated coverage of Innoviva, Inc. (NASDAQ:INVA) with an Outperform rating and $35 price target. The firm told investors tha ...